{"Title": "Adding celecoxib with or without zoledronic acid for hormone-na\u00efve prostate cancer: Long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial", "Year": 2017, "Source": "J. Clin. Oncol.", "Volume": "35", "Issue": 14, "Art.No": null, "PageStart": 1530, "PageEnd": 1541, "CitedBy": 27, "DOI": "10.1200/JCO.2016.69.0677", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019116493&origin=inward", "Abstract": "\u00a9 2017 by American Society of Clinical Oncology.Purpose: Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally advanced or metastatic prostate cancer who were initiating long-term hormone therapy. We report survival data for two celecoxib (Cel)-containing comparisons, which stopped accrual early at interim analysis on the basis of failure-free survival. Patients and Methods: Standard of care (SOC) was hormone therapy continuously (metastatic) or for \u2265 2 years (nonmetastatic); prostate (\u00b1 pelvic node) radiotherapy was encouraged for men without metastases. Cel 400 mg was administered twice a day for 1 year. Zoledronic acid (ZA) 4 mg was administered for six 3-weekly cycles, then 4-weekly for 2 years. Stratified random assignment allocated patients 2:1:1 to SOC (control), SOC + Cel, or SOC + ZA + Cel. The primary outcome measure was all-cause mortality. Results were analyzed with Cox proportional hazards and flexible parametric models adjusted for stratification factors. Results: A total of 1,245 men were randomly assigned (Oct 2005 to April 2011). Groups were balanced: median age, 65 years; 61% metastatic, 14% N+/X M0, 25% N0M0; 94% newly diagnosed; median prostate-specific antigen, 66 ng/mL. Median follow-up was 69 months. Grade 3 to 5 adverse events were seen in 36% SOC-only, 33% SOC + Cel, and 32% SOC + ZA + Cel patients. There were 303 control arm deaths (83% prostate cancer), and median survival was 66 months. Compared with SOC, the adjusted hazard ratio was 0.98 (95% CI, 0.80 to 1.20; P = .847; median survival, 70 months) for SOC + Cel and 0.86 (95% CI, 0.70 to 1.05; P =.130; median survival, 76 months) for SOC + ZA + Cel. Preplanned subgroup analyses in men with metastatic disease showed a hazard ratio of 0.78 (95% CI, 0.62 to 0.98; P = .033) for SOC + ZA + Cel. Conclusion: These data show no overall evidence of improved survival with Cel. Preplanned subgroup analyses provide hypotheses for future studies.", "AuthorKeywords": null, "IndexKeywords": ["Adult", "Aged", "Aged, 80 and over", "Antineoplastic Combined Chemotherapy Protocols", "Cause of Death", "Celecoxib", "Diphosphonates", "Disease-Free Survival", "Early Termination of Clinical Trials", "Follow-Up Studies", "Gonadotropin-Releasing Hormone", "Humans", "Imidazoles", "Lymphatic Metastasis", "Male", "Middle Aged", "Orchiectomy", "Proportional Hazards Models", "Prostate-Specific Antigen", "Prostatic Neoplasms", "Survival Rate", "Time Factors"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85019116493", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"7201987236": {"Name": "Mason M.D.", "AuthorID": "7201987236", "AffiliationID": "60103683, 60016901", "AffiliationName": "Cardiff University School of Medicine, Velindre Hospital"}, "7402350524": {"Name": "Barber J.", "AuthorID": "7402350524", "AffiliationID": "60016901", "AffiliationName": "Velindre Cancer Centre"}, "7201772622": {"Name": "Clarke N.W.", "AuthorID": "7201772622", "AffiliationID": "112818542", "AffiliationName": "Christie and Salford Royal NHS Foundation Trusts"}, "7005945304": {"Name": "Logue J.", "AuthorID": "7005945304", "AffiliationID": "60028784", "AffiliationName": "Christie Hospital"}, "7101943950": {"Name": "James N.D.", "AuthorID": "7101943950", "AffiliationID": "105637912", "AffiliationName": "Queen Elizabeth Hospital"}, "56034857000": {"Name": "Porfiri E.", "AuthorID": "56034857000", "AffiliationID": "60026493", "AffiliationName": "University Hospitals Birmingham NHS Foundation Trust"}, "7004428943": {"Name": "Dearnaley D.P.", "AuthorID": "7004428943", "AffiliationID": "60017166, 60010337", "AffiliationName": "Institute of Cancer Research, Royal Marsden NHS Foundation Trust"}, "9740870900": {"Name": "Attard G.", "AuthorID": "9740870900", "AffiliationID": "60017166, 60010337", "AffiliationName": "Institute of Cancer Research, Royal Marsden NHS Foundation Trust"}, "7402174556": {"Name": "Parker C.C.", "AuthorID": "7402174556", "AffiliationID": "60017166, 60010337", "AffiliationName": "Institute of Cancer Research, Royal Marsden NHS Foundation Trust"}, "56222417700": {"Name": "Spears M.R.", "AuthorID": "56222417700", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit, UCL"}, "7101982115": {"Name": "Ritchie A.W.S.", "AuthorID": "7101982115", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit, UCL"}, "56222016300": {"Name": "Schiavone F.", "AuthorID": "56222016300", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit, UCL"}, "56221680700": {"Name": "Matheson D.", "AuthorID": "56221680700", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit, UCL"}, "56222126300": {"Name": "Millman R.", "AuthorID": "56222126300", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit, UCL"}, "56610015700": {"Name": "Gilson C.", "AuthorID": "56610015700", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit, UCL"}, "7102310808": {"Name": "Parmar M.K.B.", "AuthorID": "7102310808", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit, UCL"}, "55836382400": {"Name": "Sydes M.R.", "AuthorID": "55836382400", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit, UCL"}, "7005462582": {"Name": "Cross W.", "AuthorID": "7005462582", "AffiliationID": "60012508", "AffiliationName": "Leeds Teaching Hospitals NHS Trust"}, "55547120726": {"Name": "Jones R.J.", "AuthorID": "55547120726", "AffiliationID": "60000265", "AffiliationName": "Beatson West of Scotland Cancer Centre"}, "7404208954": {"Name": "Russell J.M.", "AuthorID": "7404208954", "AffiliationID": "60001490", "AffiliationName": "University of Glasgow"}, "57191865079": {"Name": "Wallace J.", "AuthorID": "57191865079", "AffiliationID": "60000265", "AffiliationName": "Beatson West of Scotland Cancer Centre"}, "57194191665": {"Name": "Ibrahim A.", "AuthorID": "57194191665", "AffiliationID": "60020939", "AffiliationName": "Clatterbridge Cancer Centre NHS Foundation Trust"}, "57205070128": {"Name": "Lydon A.", "AuthorID": "57205070128", "AffiliationID": "60010647", "AffiliationName": "Torbay District Hospital"}, "55565430100": {"Name": "Nikapota A.D.", "AuthorID": "55565430100", "AffiliationID": "60028549", "AffiliationName": "Worthing Hospital"}, "7201881233": {"Name": "O'Sullivan J.M.", "AuthorID": "7201881233", "AffiliationID": "60029738", "AffiliationName": "Centre for Cancer Research and Cell Biology, Queen's University"}, "8922675100": {"Name": "Protheroe A.", "AuthorID": "8922675100", "AffiliationID": "60021328", "AffiliationName": "Churchill Hospital"}, "55122379100": {"Name": "Srihari N.N.", "AuthorID": "55122379100", "AffiliationID": "60004553", "AffiliationName": "Shrewsbury and Telford Hospitals NHS Trust"}, "57014619900": {"Name": "Tsang D.", "AuthorID": "57014619900", "AffiliationID": "60170321", "AffiliationName": "Basildon Hospital"}, "7004450477": {"Name": "Wagstaff J.", "AuthorID": "7004450477", "AffiliationID": "60170471", "AffiliationName": "Swansea University College of Medicine"}, "57194193960": {"Name": "Walmsley C.", "AuthorID": "57194193960", "AffiliationID": "60010985", "AffiliationName": "Royal Preston Hospital"}, "57203030392": {"Name": "Thalmann G.N.", "AuthorID": "57203030392", "AffiliationID": "105249754", "AffiliationName": "University Hospital"}, "8865172300": {"Name": "Cassoly E.", "AuthorID": "8865172300", "AffiliationID": "60102619", "AffiliationName": "SAKK Coordinating Center"}, "6603490451": {"Name": "Rentsch C.A.", "AuthorID": "6603490451", "AffiliationID": "60028287", "AffiliationName": "University Hospital Basel"}, "null": {"Name": null, "AuthorID": null, "AffiliationID": null, "AffiliationName": null}}}